The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
The billionaire recently stepped down as chairman of Vivendi.
Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.
Takeda investors unhappy with preliminary Shire deal; New drug sales drive Amgen earnings; Novartis debuts mobile app for eye disease study.
But threats to the industry loom as brands take work in-house.
HealthyWomen's CEO dishes on the #KeeptheCare initiative, and the rigors of activism and advocacy in the digital age.
Express Scripts pressures Amgen on migraine medicine list price; Takeda, Shire get closer to deal; Sanofi R&D chief steps down.
Takeda makes higher offer for Shire; Prothena pulls plug on AL amyloidosis drug; Henry Schein to spin off animal health unit.
A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'
Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.
Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.
Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.
Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.
Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.
Seifert said feedback from clients has been positive.
As with most drug pricing battles, patients yet again are caught in the crossfire.
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.